External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<div><div><div><div><ul><li>PYC has announced follow-up data from the second patient in its Phase 1/2 study assessing VP-001 for Retinitis Pigmentosa 11 (RP11), a rare blinding eye disease.</li><li>While the program is early in nature, we like the correlated dose response and consistent human, NHP and retina-in-dish data.</li><li>There are a number of anticipated near-term potential catalysts around PYC's clinical and nearing-clinical programs which could provide ongoing opportunities for de-risking value-inflection points.</li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC has announced follow-up data from the second patient in its Phase 1/2 study assessing VP-001 for Retinitis Pigmentosa 11 (RP11), a rare blinding eye disease.While the program is early in nature, we like the correlated dose response and consistent human, NHP and retina-in-dish data.There are a number of anticipated near-term potential catalysts around PYC's clinical and nearing-clinical programs which could provide ongoing opportunities for de-risking value-inflection points.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - Ticking the Boxes with Two Patients at Four Months with VP-001